The deal adds to Kerry’s breadth of probiotic capabilities. Kerry first acquired Cleveland, OH-based Ganeden and its BC-30 Bacillus coagulans ingredient in 2017. The company followed that with the acquisition of Canadian probiotic manufacturer Bio-K+ International in 2020. And it continued to build a powerhouse probiotic portfolio with the acquisition of Spanish probiotics developer Biosearch Life earlier this year.
The MB40 ingredient is a proprietary strain of Bacillus subtilis (strain no. ATCC122264), which like the BC-30 ingredient, is a spore-forming organism, which presumably will confer some formulation flexibility compared to standard probiotics.
A parallel-design study done with the ingredient in 2019 showed that it reduced bloating vs placebo for some groups. According to Kerry’s analysis, the study “demonstrated promising results for the probiotic strain to support gastrointestinal health.”
"Given the impressive performance of the MB40 strain and its potential to have a significant impact on the dietary supplement, functional food and beverage, and companion animal industries, we have decided to work with a partner who will help scale MB40 globally," said Chris Schuler, CEO of BIO-CAT.
"Kerry's expertise, commitment to develop a leading probiotic platform, access to global resources, and plans to further scientifically support MB40 make them an ideal partner,” he added.
Brand ‘refresh’
As part of the deal Kerry will take over the brand presentation for MB40. A ‘refresh’ of the brand will be undertaken, which reportedly will be completed within several months. Then the brand will be offered through Kerry’s 150 sales locations in 31 countries around the globe.
Kerry extends growing probiotic line with marketing deal covering spore forming ingredient - NutraIngredients-usa.com
Read More
No comments:
Post a Comment